Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Breaking the Fungal Biofilm with Q-Switched Nd: Yag Laser and Black Peel: Species-Blind Non-pharmacological Eradication of Azole-Resistant Onychomycosis

Amarendra Pandey

Background: Onychomycosis (ONM), hitherto an easily manageable problem, more commonly seen in elderly patients has unfortunately transformed into an extremely-difficult-to-treat nail disorder, especially due to the widespread azole resistance. Not only has the azole resistance become a reason of treatment failure with itraconazole or ITRA (the usual drug of choice), the azole-induced cross-resistance to oral terbinafine and topical amorolofine has rendered ONM caused by dermatophytes, yeasts as well as molds to multi-drug-resistant (MDR) ONM, refractory to all forms of pharmacological interventions. The problem is reaching epidemic proportions in South Asian Countries. The use of ITRA further becomes impossible in the elderly who are not only on polypharmacy (owing to plethora of drug-interactions of ITRA), but also stemming from its absolute contraindication in patients with any disease that has impaired or has the potential to compromise the patient’s cardiac function. Dermatologists across the Asia-Pacific are finding it difficult to treat all forms of ONM, especially because most have been rendered azole-resistant due to unscrupulous use of ITRA with respect to wrong dosage, duration and dietary-intake instructions due to wrong prescription by non-specialists and/or selfuse by the patients.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.